Literature DB >> 10063477

Rapid detection of toxigenic Clostridium difficile from stool samples by a nested PCR of toxin B gene.

R Alonso1, C Muñoz, S Gros, D García de Viedma, T Peláez, E Bouza.   

Abstract

Toxigenic Clostridium difficile is the aetiologic agent of most cases of antibiotic-associated diarrhoea and pseudomembranous colitis. The present standard method for C. difficile diagnosis is a cytotoxicity assay, performed on human fibroblast cultures. It is time consuming and requires special facilities. A nested-PCR assay detecting toxin B gene within a few hours was designed. One hundred and two stool samples were collected during four months. All samples were processed for toxin B-PCR, cultured for C. difficile and tested for cytotoxicity. This approach achieved 99% concordance with the cytotoxic assay. The sensitivity and specificity for the new PCR assay were 96.3% and 100% respectively. The procedure described is easy to perform, does not require special equipment and has produced excellent results. It deserves serious consideration for routine clinical microbiology laboratory use.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10063477     DOI: 10.1016/s0195-6701(99)90052-x

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  12 in total

Review 1.  Molecular techniques for diagnosis of Clostridium difficile infection: systematic review and meta-analysis.

Authors:  John C O'Horo; Amy Jones; Matthew Sternke; Christopher Harper; Nasia Safdar
Journal:  Mayo Clin Proc       Date:  2012-07       Impact factor: 7.616

2.  Evaluation of two rapid immunochromatography tests for the detection of Clostridium difficile toxins.

Authors:  Zmira Samra; Avia Luzon; Jihad Bishara
Journal:  Dig Dis Sci       Date:  2007-11-08       Impact factor: 3.199

3.  Development and evaluation of a PCR method for detection of the Clostridium difficile toxin B gene in stool specimens.

Authors:  C Guilbault; A-C Labbé; L Poirier; L Busque; C Béliveau; M Laverdière
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

4.  Rapid and simple method for detecting the toxin B gene of Clostridium difficile in stool specimens by loop-mediated isothermal amplification.

Authors:  Haru Kato; Toshiyuki Yokoyama; Hideaki Kato; Yoshichika Arakawa
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

Review 5.  Update on Clostridium difficile infection.

Authors:  C S Alcantara; R L Guerrant
Journal:  Curr Gastroenterol Rep       Date:  2000-08

6.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship.

Authors:  Udayakumar Navaneethan; Preethi Gk Venkatesh; Bo Shen
Journal:  World J Gastroenterol       Date:  2010-10-21       Impact factor: 5.742

8.  Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms.

Authors:  Susan M Novak-Weekley; Elizabeth M Marlowe; John M Miller; Joven Cumpio; Jim H Nomura; Paula H Vance; Alice Weissfeld
Journal:  J Clin Microbiol       Date:  2010-01-13       Impact factor: 5.948

9.  Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection.

Authors:  Elizabeth J Kvach; David Ferguson; Paul F Riska; Marie L Landry
Journal:  J Clin Microbiol       Date:  2009-10-28       Impact factor: 5.948

10.  Comparison of a rapid molecular method, the BD GeneOhm Cdiff assay, to the most frequently used laboratory tests for detection of toxin-producing Clostridium difficile in diarrheal feces.

Authors:  Gabriella Terhes; Edit Urbán; József Sóki; Eniko Nacsa; Elisabeth Nagy
Journal:  J Clin Microbiol       Date:  2009-09-30       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.